JNJNYSEHealthcare

JOHNSON & JOHNSON

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$276.22

+1.43%

Alpha Vantage · 11/6/2026

Industry: Drug Manufacturers - GeneralCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze JNJ free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+7.7%

3 months

+6.0%

6 months

+26.1%

1 year

+51.1%

Year to date

+35.6%

52-week range

$182.47 – $278.43

Fundamental snapshot

Latest reported period: Sep 27, 2026

Sharadar reported data

Market cap

$664.95B

P/E

41.3

P/B

8.2

P/S

6.7

Revenue

$99.34B

Net income

$16.1B

Diluted EPS

6.58

Gross margin

67.60%

Net margin

16.20%

Return on equity

19.60%

Total debt

$44.65B

Cash

$16.91B

Free cash flow

$20.59B

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 27, 2026	$25.4B	$210M	68.10%	0.80%	$6.36B
Jun 28, 2026	$25.31B	$5.53B	68.20%	21.90%	$7.3B
Mar 29, 2026	$24.06B	$5.24B	66.30%	21.80%	$1.47B
Dec 28, 2025	$24.56B	$5.12B	67.60%	20.80%	$5.47B
Sep 28, 2025	$23.99B	$5.15B	69.60%	21.50%	$8.01B
Jun 29, 2025	$23.74B	$5.54B	67.90%	23.30%	$2.84B
Mar 30, 2025	$21.89B	$11B	66.40%	50.20%	$3.38B
Dec 29, 2024	$22.52B	$3.43B	68.30%	15.20%	$5.37B

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent JNJ news

All market news

Benzinga·Oct 28, 202670 signal

Bausch Health Companies Q3 2026 Earnings Call Transcript

Bausch Health Companies reported strong third-quarter results, exceeding $1 billion in quarterly adjusted EBITDA for the first time and marking 14 consecutive quarters of growth. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow, driven by strong performance in Salix, International, and Solta Medical segments. Management also discussed debt reduction efforts, capital allocation, and future strategic priorities, including pipeline development and operational excellence, while acknowledging anticipated Q4 headwinds related to Xifaxan.

Original source